Pharmacogenomics of warfarin in populations of African descent

British Journal of Clinical Pharmacology

Volumn 75, Issue 2, 2013, Pages 334-346

  Suarez Kurtz, Guilherme ^a   Botton, Mariana R ^b  

^a Instituto Nacional de Cncer   (Brazil)

^b FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

Author keywords

African ancestry; CYP2C9; Global pharmacogenomics; Population diversity; VKORC1; Warfarin algorithms

Indexed keywords

APOLIPOPROTEIN E; BLOOD CLOTTING FACTOR 7; CALUMENIN; CHAPERONE; CYTOCHROME P450 2C9; CYTOCHROME P450 F2; UNCLASSIFIED DRUG; VITAMIN K DEPENDENT CARBOXYLASE; VITAMIN K EPOXIDE REDUCTASE COMPLEX 1; WARFARIN;

AFRICA; AFRICAN AMERICAN; ALGORITHM; ARTICLE; BRAZIL; COST EFFECTIVENESS ANALYSIS; CULTURAL FACTOR; DRUG SAFETY; EUROPE; GENETIC HETEROGENEITY; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; PHARMACOGENETICS; PHARMACOGENOMICS; POPULATION GENETICS; PREDICTION; PRIORITY JOURNAL; RACE DIFFERENCE; SOCIOECONOMICS;

AFRICAN CONTINENTAL ANCESTRY GROUP; ALGORITHMS; ANTICOAGULANTS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; PHARMACOGENETICS; POLYMORPHISM, GENETIC; WARFARIN;

EID: 84872236997     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2012.04354.x     Document Type: Article

References (64)

1. Kalow W. Pharmacogenetics, Heredity and the Response to Drugs. Philadelphia, PA: W.B Saunders Co., 1962.
2. Pääbo S. The mosaic that is our genome. Nature 2003; 421: 409-412.
3. Pena SD, Di Pietro G, Fuchshuber-Moraes M, Genro JP, Hutz MH, Kehdy FeS, Kohlrausch F, Magno LA, Montenegro RC, Moraes MO, de Moraes ME, de Moraes MR, Ojopi EB, Perini JA, Racciopi C, Ribeiro-Dos-Santos AK, Rios-Santos F, Romano-Silva MA, Sortica VA, Suarez-Kurtz G. The genomic ancestry of individuals from different geographical regions of Brazil is more uniform than expected. PLoS ONE 2011; 6: e17063.
4. Suarez-Kurtz G. Pharmacogenetics in the Brazilian population. Front Pharmacogenet 2010; 1: 1-10.
5. Parra EJ, Suarez-Kurtz G. Admixture in North America. In: Pharmacogenomics in Admixed Populations, ed. Suarez-Kurtz G. Austin. TX: Landes Bioscience, 2007; 28-46.
6. Bryc K, Auton A, Nelson MR, Oksenberg JR, Hauser SL, Williams S, Froment A, Bodo JM, Wambebe C, Tishkoff SA, Bustamante CD. Genome-wide patterns of population structure and admixture in West Africans and African Americans. Proc Natl Acad Sci U S A 2010; 107: 786-791.
7. Parra EJ, Kittles RA, Shriver MD. Implications of correlations between skin color and genetic ancestry for biomedical research. Nat Genet 2004; 36: S54-60.
8. Suarez-Kurtz G, Perini JA, Bastos-Rodrigues L, Pena SD, Struchiner C. Impact of population admixture on the distribution of the CYP3A5*3 polymorphism. Pharmacogenomics 2007; 8: 1299-1306.
9. Suarez-Kurtz G, Amorim A, Damasceno A, Hutz MH, de Moraes MO, Ojopi EB, Pena SD, Perini JA, Prata MJ, Ribeiro-dos-Santos A, Romano-Silva MA, Teixeira D, Struchiner CJ. VKORC1 polymorphisms in Brazilians: comparison with the Portuguese and Portuguese-speaking Africans and pharmacogenetic implications. Pharmacogenomics 2010; 11: 1257-1267.
10. Tishkoff SA, Reed FA, Friedlaender FR, Ehret C, Ranciaro A, Froment A, Hirbo JB, Awomoyi AA, Bodo JM, Doumbo O, Ibrahim M, Juma AT, Kotze MJ, Lema G, Moore JH, Mortensen H, Nyambo TB, Omar SA, Powell K, Pretorius GS, Smith MW, Thera MA, Wambebe C, Weber JL, Williams SM. The genetic structure and history of Africans and African Americans. Science 2009; 324: 1035-1044.
11. Loebstein R, Dvoskin I, Halkin H, Vecsler M, Lubetsky A, Rechavi G, Amariglio N, Cohen Y, Ken-Dror G, Almog S, Gak E. A coding VKORC1 Asp36Tyr polymorphism predisposes to warfarin resistance. Blood 2007; 109: 2477-2480.
12. Shahin MH, Khalifa SI, Gong Y, Hammad LN, Sallam MT, El Shafey M, Ali SS, Mohamed ME, Langaee T, Johnson JA. Genetic and nongenetic factors associated with warfarin dose requirements in Egyptian patients. Pharmacogenet Genomics 2011; 21: 130-135.
13. Cavallari LH, Momary KM, Patel SR, Shapiro NL, Nutescu E, Viana MA. Pharmacogenomics of warfarin dose requirements in Hispanics. Blood Cells Mol Dis 2011; 46: 147-150.
14. Gage BF, Eby C, Johnson JA, Deych E, Rieder MJ, Ridker PM, Milligan PE, Grice G, Lenzini P, Rettie AE, Aquilante CL, Grosso L, Marsh S, Langaee T, Farnett LE, Voora D, Veenstra DL, Glynn RJ, Barrett A, McLeod HL. Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin Pharmacol Ther 2008; 84: 326-331.
15. Kimmel SE, Christie J, Kealey C, Chen Z, Price M, Thorn CF, Brensinger CM, Newcomb CW, Whitehead AS. Apolipoprotein E genotype and warfarin dosing among Caucasians and African Americans. Pharmacogenomics J 2008; 8: 53-60.
16. Klein TE, Altman RB, Eriksson N, Gage BF, Kimmel SE, Lee MTM, Limdi NA, Page D, Roden DM, Wagner MJ, Caldwell MD, Johnson JA, Chen YT, Wen MS, Caraco Y, Achache I, Blotnick S, Muszkat M, Shin JG, Kim HS, Suarez-Kurtz G, Perini JA, Silva-Assuncao E, Andereson JL, Horne BD, Carlquist JF, Berg RL, Burmester JK, Goh BC, Lee SC, Kamali F, Sconce E, Daly AK, Wu AHB, Langaee TY, Feng H, Cavallari L, Momary K, Pirmohamed M, Jorgensen A, Toh CH, Williamson P, McLeod H, Evans JP, Weck KE, Brensinger C, Nakamura Y, Mushiroda T, Veenstra D, Meckley L, Rieder MJ, Rettie AE, Wadelius M, Melhus H, Stein CM, Schwartz U, Kurnik D, Deych E, Lenzini P, Eby C, Chen LY, Deloukas P, Motsinger-Reif A, Sagreiya H, Srinivasan BS, Lantz E, Chang T, Ritchie M, Lu LS. Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med 2009; 360: 753-764.
17. Limdi NA, Wadelius M, Cavallari L, Eriksson N, Crawford DC, Lee MT, Chen CH, Motsinger-Reif A, Sagreiya H, Liu N, Wu AH, Gage BF, Jorgensen A, Pirmohamed M, Shin JG, Suarez-Kurtz G, Kimmel SE, Johnson JA, Klein TE, Wagner MJ, Consortium IWP. Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups. Blood 2010; 115: 3827-3834.
18. Voora D, Koboldt DC, King CR, Lenzini PA, Eby CS, Porche-Sorbet R, Deych E, Crankshaw M, Milligan PE, McLeod HL, Patel SR, Cavallari LH, Ridker PM, Grice GR, Miller RD, Gage BF. A polymorphism in the VKORC1 regulator calumenin predicts higher warfarin dose requirements in African Americans. Clin Pharmacol Ther 2010; 87: 445-451.
19. Perini JA, Struchiner CJ, Silva-Assuncao E, Santana ISC, Rangel F, Ojopi EB, Dias-Neto E, Suarez-Kurtz G. Pharmacogenetics of warfarin: development of a dosing algorithm for Brazilian patients. Clin Pharmacol Ther 2008; 84: 722-728.
20. Allabi AC, Gala JL, Horsmans Y. CYP2C9, CYP2C19, ABCB1 (MDR1) genetic polymorphisms and phenytoin metabolism in a Black Beninese population. Pharmacogenet Genomics 2005; 15: 779-786.
21. Liu Y, Jeong H, Takahashi H, Drozda K, Patel SR, Shapiro NL, Nutescu EA, Cavallari LH. Decreased warfarin clearance associated with the CYP2C9 R150H (*8) polymorphism. Clin Pharmacol Ther 2012; 91: 660-665.
22. Mitchell C, Gregersen N, Krause A. Novel CYP2C9 and VKORC1 gene variants associated with warfarin dosage variability in the South African black population. Pharmacogenomics 2011; 12: 953-963.
23. Scott SA, Jaremko M, Lubitz SA, Kornreich R, Halperin JL, Desnick RJ. CYP2C9*8 is prevalent among African-Americans: implications for pharmacogenetic dosing. Pharmacogenomics 2009; 10: 1243-1255.
24. Cavallari LH, Langaee TY, Momary KM, Shapiro NL, Nutescu EA, Coty WA, Viana MA, Patel SR, Johnson JA. Genetic and clinical predictors of warfarin dose requirements in African Americans. Clin Pharmacol Ther 2010; 87: 459-464.
25. The Human Cytochrome P450 (CYP) Allele Nomenclature Database. CYP2C9 allele nomenclature. Available at http://www.cypalleles.ki.se/cyp2c9.htm (last accessed 18 May 2012).
26. Perera MA, Gamazon E, Cavallari LH, Patel SR, Poindexter S, Kittles RA, Nicolae D, Cox NJ. The missing association: sequencing-based discovery of novel SNPs in VKORC1 and CYP2C9 that affect warfarin dose in African Americans. Clin Pharmacol Ther 2011; 89: 408-415.
27. Cavallari LH, Perera M, Wadelius M, Deloukas P, Taube G, Patel SR, Aquino-Michaels K, Viana MA, Shapiro NL, Nutescu EA. Association of the GGCX (CAA)16/17 repeat polymorphism with higher warfarin dose requirements in African Americans. Pharmacogenet Genomics 2012; 22: 152-158.
28. Shrif NE, Won HH, Lee ST, Park JH, Kim KK, Kim MJ, Kim S, Lee SY, Ki CS, Osman IM, Rhman EA, Ali IA, Idris MN, Kim JW. Evaluation of the effects of VKORC1 polymorphisms and haplotypes, CYP2C9 genotypes, and clinical factors on warfarin response in Sudanese patients. Eur J Clin Pharmacol 2011; 67: 1119-1130.
29. Limdi NA, Arnett DK, Goldstein JA, Beasley TM, McGwin G, Adler BK, Acton RT. Influence of CYP2C9 and VKORC1 on warfarin dose, anticoagulation attainment and maintenance among European-Americans and African-Americans. Pharmacogenomics 2008; 9: 511-526.
30. Momary KM, Shapiro NL, Viana MA, Nutescu EA, Helgason CM, Cavallari LH. Factors influencing warfarin dose requirements in African-Americans. Pharmacogenomics 2007; 8: 1535-1544.
31. Wang D, Chen H, Momary KM, Cavallari LH, Johnson JA, Sadée W. Regulatory polymorphism in vitamin K epoxide reductase complex subunit 1 (VKORC1) affects gene expression and warfarin dose requirement. Blood 2008; 112: 1013-1021.
32. Schelleman H, Brensinger CM, Chen J, Finkelman BS, Rieder MJ, Kimmel SE. New genetic variant that might improve warfarin dose prediction in African Americans. Br J Clin Pharmacol 2010; 70: 393-399.
33. Limdi NA, Beasley TM, Crowley MR, Goldstein JA, Rieder MJ, Flockhart DA, Arnett DK, Acton RT, Liu N. VKORC1 polymorphisms, haplotypes and haplotype groups on warfarin dose among African-Americans and European-Americans. Pharmacogenomics 2008; 9: 1445-1458.
34. Harrington DJ, Underwood S, Morse C, Shearer MJ, Tuddenham EG, Mumford AD. Pharmacodynamic resistance to warfarin associated with a Val66Met substitution in vitamin K epoxide reductase complex subunit 1. Thromb Haemost 2005; 93: 23-26.
35. Orsi FA, Annichino Bizzacchi JM, De Paula EV, Ozelo MC, Langley MR, Weck KE. VKORC1 V66M mutation in African Brazilian patients resistant to oral anticoagulant therapy. Thromb Res 2010; 126: e206-210.
36. Aklillu E, Leong C, Loebstein R, Halkin H, Gak E. VKORC1 Asp36Tyr warfarin resistance marker is common in Ethiopian individuals. Blood 2008; 111: 3903-3904.
37. Crawford DC, Brown-Gentry K, Rieder MJ. VKORC1 common variation and bone mineral density in the Third National Health and Nutrition Examination Survey. PLoS ONE 2010; 5: e15088.
38. Pautas E, Moreau C, Gouin-Thibault I, Golmard JL, Mahe I, Legendre C, Taillandier-Heriche E, Durand-Gasselin B, Houllier AM, Verrier P, Beaune P, Loriot MA, Siguret V. Genetic factors (VKORC1, CYP2C9, EPHX1, and CYP4F2) are predictor variables for warfarin response in very elderly, frail inpatients. Clin Pharmacol Ther 2010; 87: 57-64.
39. Ciccacci C, Paolillo N, Di Fusco D, Novelli G, Borgiani P. EPHX1 polymorphisms are not associated with warfarin response in an Italian population. Clin Pharmacol Ther 2011; 89: 791.
40. Ramirez AH, Shi Y, Schildcrout JS, Delaney JT, Xu H, Oetjens MT, Zuvich RL, Basford MA, Bowton E, Jiang M, Speltz P, Zink R, Cowan J, Pulley JM, Ritchie MD, Masys DR, Roden DM, Crawford DC, Denny JC. Predicting warfarin dosage in European-Americans and African-Americans using DNA samples linked to an electronic health record. Pharmacogenomics 2012; 13: 407-418.
41. Cavallari LH, Butler C, Langaee TY, Wardak N, Patel SR, Viana MA, Shapiro NL, Nutescu EA. Association of apolipoprotein E genotype with duration of time to achieve a stable warfarin dose in African-American patients. Pharmacotherapy 2011; 31: 785-792.
42. Schelleman H, Chen Z, Kealey C, Whitehead AS, Christie J, Price M, Brensinger CM, Newcomb CW, Thorn CF, Samaha FF, Kimmel SE. Warfarin response and vitamin K epoxide reductase complex 1 in African Americans and Caucasians. Clin Pharmacol Ther 2007; 81: 742-747.
43. Kimura R, Miyashita K, Kokubo Y, Akaiwa Y, Otsubo R, Nagatsuka K, Otsuki T, Okayama A, Minematsu K, Naritomi H, Honda S, Tomoike H, Miyata T. Genotypes of vitamin K epoxide reductase, gamma-glutamyl carboxylase, and cytochrome P4502C9 as determinants of daily warfarin dose in Japanese patients. Thromb Res 2007; 120: 181-186.
44. Wadelius M, Chen LY, Downes K, Ghori J, Hunt S, Eriksson N, Wallerman O, Melhus H, Wadelius C, Bentley D, Deloukas P. Common VKORC1 and GGCX polymorphisms associated with warfarin dose. Pharmacogenomics J 2005; 5: 262-270.
45. Wajih N, Sane DC, Hutson SM, Wallin R. The inhibitory effect of calumenin on the vitamin K-dependent gamma-carboxylation system - characterization of the system in normal and warfarin-resistant rats. J Biol Chem 2004; 279: 25276-25283.
46. Takeuchi F, McGinnis R, Bourgeois S, Barnes C, Eriksson N, Soranzo N, Whittaker P, Ranganath V, Kumanduri V, McLaren W, Holm L, Lindh J, Rane A, Wadelius M, Deloukas P. A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. PLoS Genet 2009; 5: e1000433.
47. National Center for Biotechnology Information - dbSNP. Database of single nucleotide polymorphisms. Available at http://www.ncbi.nlm.nih.gov/projects/SNP/snprefcgi?rs=2108622 (last accessed 18 May 2012).
48. Perini JA, Struchiner CJ, Silva-Assuncao E, Suarez-Kurtz G. Impact of CYP4F2 rs2108622 on the stable warfarin dose in an admixed patient cohort. Clin Pharmacol Ther 2010; 87: 417-420.
49. Schelleman H, Chen J, Chen Z, Christie J, Newcomb CW, Brensinger CM, Price M, Whitehead AS, Kealey C, Thorn CF, Samaha FF, Kimmel SE. Dosing algorithms to predict warfarin maintenance dose in Caucasians and African Americans. Clin Pharmacol Ther 2008; 84: 332-339.
50. Fuchshuber-Moraes M, Perini JA, Rosskopf D, Suarez-Kurtz G. Exploring warfarin pharmacogenomics with the extreme-discordant-phenotype methodology: impact of FVII polymorphisms on stable anticoagulation with warfarin. Eur J Clin Pharmacol 2009; 65: 789-793.
51. Nebert DW. Extreme discordant phenotype methodology: an intuitive approach to clinical pharmacogenetics. Eur J Pharmacol 2000; 410: 107-120.
52. Suarez-Kurtz G. Population diversity and the performance of warfarin dosing algorithms. Br J Clin Pharmacol 2011; 72: 451-453.
53. Cosgun E, Limdi NA, Duarte CW. High-dimensional pharmacogenetic prediction of a continuous trait using machine learning techniques with application to warfarin dose prediction in African Americans. Bioinformatics 2011; 27: 1384-1389.
54. Kealey C, Chen Z, Christie J, Thorn CF, Whitehead AS, Price M, Samaha FF, Kimmel SE. Warfarin and cytochrome P450 2C9 genotype: possible ethnic variation in warfarin sensitivity. Pharmacogenomics 2007; 8: 217-225.
55. Takahashi H, Wilkinson GR, Nutescu EA, Morita T, Ritchie MD, Scordo MG, Pengo V, Barban M, Padrini R, Ieiri I, Otsubo K, Kashima T, Kimura S, Kijima S, Echizen H. Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans. Pharmacogenet Genomics 2006; 16: 101-110.
56. Wu AH, Wang P, Smith A, Haller C, Drake K, Linder M, Valdes R. Dosing algorithm for warfarin using CYP2C9 and VKORC1 genotyping from a multi-ethnic population: comparison with other equations. Pharmacogenomics 2008; 9: 169-178.
57. Suarez-Kurtz G, Genro JP, de Moraes MO, Ojopi EB, Pena SD, Perini JA, Ribeiro-Dos-Santos A, Romano-Silva MA, Santana I, Struchiner CJ. Global pharmacogenomics: impact of population diversity on the distribution of polymorphisms in the CYP2C cluster among Brazilians. Pharmacogenomics J 2012; 12: 267-276.
58. Vargens DD, Damasceno A, Petzl-Erler ML, Suarez-Kurtz G. Combined CYP2C9, VKORC1 and CYP4F2 frequencies among Amerindians, Mozambicans and Brazilians. Pharmacogenomics 2011; 12: 769-772.
59. Rede Nacional de Farmacogenética. The Brazilian Pharmacogenomic Network. Available at http://www.refargen.org.br (last accessed 18 May 2012).
60. Dandara C, Lombard Z, Du Plooy I, McLellan T, Norris SA, Ramsay M. Genetic variants in CYP (-1A2, -2C9, -2C19, -3A4 and -3A5), VKORC1 and ABCB1 genes in a black South African population: a window into diversity. Pharmacogenomics 2011; 12: 1663-1670.
61. The International Project. Available at http://hapmap.ncb.inlm.nih.gov/ (last accessed 18 May 2012).
62. Allabi AC, Horsmans Y, Alvarez JC, Bigot A, Verbeeck RK, Yasar U, Gala JL. Acenocoumarol sensitivity and pharmacokinetic characterization of CYP2C9 *5/*8, *8/*11, *9/*11 and VKORC1*2 in black African healthy Beninese subjects. Eur J Drug Metab Pharmacokinet 2012; 37: 125-132.
63. Scott SA, Khasawneh R, Peter I, Kornreich R, Desnick RJ. Combined CYP2C9, VKORC1 and CYP4F2 frequencies among racial and ethnic groups. Pharmacogenomics 2010; 11: 781-791.
64. Suarez-Kurtz G, Perini JA, Silva-Assunção E, Struchiner CJ. Relative contribution of VKORC1, CYP2C9, and INR response to warfarin stable dose. Blood 2009; 113: 4125-4126.